The Readout Loud podcast

Player FM - Internet Radio Done Right

0-10 subscribers

تمت الإضافة منذ قبل four أعوام

المحتوى المقدم من STAT. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة STAT أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

Lost Cultures: Living Legacies

1
Bermuda: The Crossroads of the Atlantic 51:57

منذ 21 يومًا51:57

التشغيل لاحقا

قوائم

إعجاب

احب

51:57

On the Season 2 debut of Lost Cultures: Living Legacies , we travel to Bermuda, an Atlantic island whose history spans centuries and continents. Once uninhabited, Bermuda became a vital stop in transatlantic trade, a maritime stronghold, and a cultural crossroads shaped by African, European, Caribbean, and Native American influences. Guests Dr. Kristy Warren and Dr. Edward Harris trace its transformation from an uninhabited island to a strategic outpost shaped by shipwrecks, colonization, the transatlantic slave trade, and the rise and fall of empires. Plus, former Director of Tourism Gary Phillips shares the story of the Gombey tradition, a vibrant performance art rooted in resistance, migration, and cultural fusion. Together, they reveal how Bermuda’s layered past continues to shape its people, culture, and identity today. You can also find us online at ⁠travelandleisure.com/lostcultures Learn more about your ad choices. Visit podcastchoices.com/adchoices…

The Readout Loud

منزل السلاسل•Feed

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

360 حلقات

#Business #Stats

The Readout Loud

0-10 subscribers

updated منذ 5 أيام

منزل السلاسل•Feed

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

360 حلقات

#Business #Stats

All episodes

The Readout Loud

1
356: An AI experiment at the FDA & Novo trailing in the obesity drug race 33:05

منذ 5 أيام33:05

33:05

The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can’t seem to let go of mistakes. Our colleague Brittany Trang joins to explain. And it’s always a fun podcast when we can discuss a biotech acquisition. This week, we’ll chat about Sanofi’s $9 billion offer for Blueprint Medicines. But first, our cohost Elaine Chen has a new story published this week that examines the reasons behind Novo Nordisk’s fall and what it’s doing to catch up.…

The Readout Loud

1
355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview 36:55

منذ 12 يومًا36:55

36:55

The American Society of Clinical Oncology, or ASCO, kicks off its annual meeting this weekend in Chicago. We discuss what to watch at the meeting. Then, STAT’s infectious disease reporter Helen Branswell joins us to discuss RFK Jr.’s unprecedented move to strike Covid shot recommendations, and the cancellation of a $600 million contract with Moderna to develop, test and license vaccines for subtypes of flu. We also welcome chronic disease reporter Isa Cueto to discuss the key takeaways from a closely watched report from Kennedy’s Make America Healthy Again Commission.…

The Readout Loud

1
354: Uncertainty in CRISPR world and the start of more M&A 41:30

منذ 19 يومًا41:30

41:30

We chat about M&A deals picking up, leadership changes at Novo, and recent FDA advisory committee meetings for cancer drugs. We also bring on STAT reporter Jason Mast to talk about the latest research and sentiment at the annual American Society of Cell and Gene Therapy meeting.

The Readout Loud

1
353: Trump's drug-pricing plan and a potential Theranos 2.0 25:47

منذ 26 يومًا25:47

25:47

We chat about the mixed sentiment in biotech markets these days and a new blood-testing company formed by Elizabeth Holmes' husband. We also bring on STAT's D.C. correspondent Daniel Payne to talk about President Trump's "most-favored nation" drug pricing policy and health secretary Robert F. Kennedy Jr.'s recent congressional hearing.…

The Readout Loud

1
352: A firebrand takes oversight of vaccines, gene therapies 26:28

منذ 5 weeks26:28

26:28

Matt Herper joins Adam and Allison to examine Prasad's appointment and the band of outsiders now in charge of U.S. health agencies. He and Adam debate just how disruptive Prasad's tenure could be.

The Readout Loud

1
351: It's gonna be May (in biotech) 35:19

منذ 6 weeks35:19

35:19

On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong drug launches, and Eli Lilly’s PBM problem. The first 100 days of the Trump administration have had a profound impact on federal health agencies, medical research, health policy and the biotech and pharmaceuticals industries. To help us make sense of all the cuts and policy shifts, we talk with STAT editors Gideon Gil and Zach Tracer for their perspective overseeing STAT’s reporting on science and politics. But first, your co-hosts Elaine, Allison and Adam gab about the week’s relatively positive biotech news, including two acquisitions and a series of strong drug launches. What’s a podcast without dipping into obesity, so Elaine will explain the latest maneuverings between Eli Lilly and Novo Nordisk around patient access and compounding.…

The Readout Loud

1
350: Pharma tariffs, and a 'sunshine day' for biotech stocks 31:40

منذ 7 weeks31:40

31:40

How did Ireland become a hotspot for pharmaceutical manufacturing? What are the products that will come out of Flagship's latest startup centered around "preemptive medicine"? And who among the co-hosts is the best singer? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about the recent bounceback in biotech stocks, disappointing results from Bristol Myers Squibb's schizophrenia drug Cobenfy, new allegations about entrepreneur Sam Waksal, and more. We also bring on STAT's European correspondent Drew Joseph to talk about the growth of pharma manufacturing in Ireland and how U.S. tariffs would impact global drug supply.…

The Readout Loud

1
349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding 40:55

منذ 9 weeks40:55

40:55

John Crowley, the CEO of industry lobbying group BIO, joins us to discuss the layoffs at the Food and Drug Administration, RFK Jr.'s comments on Novavax's Covid-19 vaccine, and how the trade group is communicating with the Trump administration. Then we discuss the latest news on the stock market and a congressional advisory group's recommendation that $15 billion be invested in U.S. biotechnology to ward off encroaching competition from China.…

The Readout Loud

1
348: Cuts, ousters and drama at the FDA 31:10

منذ 10 weeks31:10

31:10

STAT’s FDA reporter Lizzy Lawrence joins to discuss her inside-the-agency reporting on how Robert F. Kennedy Jr. forced top FDA officials to resign at a time when newly sworn-in FDA Commissioner Makary is still figuring out how to get around the agency’s White Oak campus in suburban Maryland. Then: AstraZeneca presented positive mid-stage results this week on a PCSK9 pill that dramatically lowered cholesterol levels on top of traditional statins. R&D executive Sharon Barr joins to talk about why AstraZeneca views this experimental cardiovascular medicine as a key part of its growth strategy.…

The Readout Loud

1
347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival 31:25

منذ 11 weeks31:25

31:25

Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, they bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development.…

The Readout Loud

1
346: Zealand's obesity strategy and Immunovant's curious development plan 42:34

منذ 12 weeks42:34

42:34

We chat about positive data from Immunovant's autoimmune drug candidate, a patient death linked to Sarepta's gene therapy, and dispatches from our STAT Breakthrough Summit East in New York. We also bring on Zealand Pharma CEO Adam Steensberg to talk about his company’s amylin-targeting obesity treatment, the partnership deal it recently signed with Roche, and his thoughts on the industry's intense focus on weight loss.…

The Readout Loud

1
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies 31:00

منذ 13 weeks31:00

31:00

We bring on our colleague Sarah Owermohle to discuss the White House's sudden move to withdraw the nomination of Dave Weldon as its pick to run the CDC just hours before Weldon's confirmation hearing. It's also the five-year anniversary of the Covid-19 pandemic. We chat with Princeton political scientist Frances Lee about a new book she co-authored that offers an unflinching assessment of the U.S. policy responses to the pandemic and raises some provocative questions about what went wrong.…

The Readout Loud

1
344: Trump's FDA commissioner nominee takes the hot seat 25:51

منذ 14 weeks25:51

25:51

Will Marty Makary be confirmed as the next commissioner of the Food and Drug Administration? Will he bring back employees laid off by DOGE? And what did he get wrong during his confirmation hearing? We discuss all that and more during this week's special episode.

The Readout Loud

1
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs 32:01

منذ 15 weeks32:01

32:01

It’s a STAT reporter two-fer guest episode. First, Lizzy Lawrence joins from D.C. to dish on the upheaval and drama taking place at the FDA. Then, we chat with Jason Mast about Bluebird Bio, its fire sale to private equity and what lies ahead for the unsettled world of genetic medicines. Before those discussions, Allison provides some insight into the “new kids” on the biotech VC block.…

The Readout Loud

1
342: FDA cuts, zombie biotechs, and too much weight loss? 41:00

منذ 16 weeks41:00

41:00

Mizuho analyst Jared Holz joins to discuss Adam's column on biotech's dark period. We also talk about Elaine's latest article on the push for greater and greater weight loss from obesity drugs, along with developments at Solid Biosciences and federal job cuts.

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.